Cargando…
The systolic paradox in hypertrophic cardiomyopathy
OBJECTIVE: We explored cardiac volumes and the effects on systolic function in hypertrophic cardiomyopathy (HCM) patients with left ventricular hypertrophy (HCM LVH+) and genotype-positive patients without left ventricular hypertrophy (HCM LVH−). METHODS: We included 180 HCM LVH+, 100 HCM LVH− patie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Heart
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471858/ https://www.ncbi.nlm.nih.gov/pubmed/28674623 http://dx.doi.org/10.1136/openhrt-2016-000571 |
_version_ | 1783244030269718528 |
---|---|
author | Haland, Trine F Hasselberg, Nina E Almaas, Vibeke Marie Dejgaard, Lars A Saberniak, Jørg Leren, Ida S Berge, Knut Erik Haugaa, Kristina H Edvardsen, Thor |
author_facet | Haland, Trine F Hasselberg, Nina E Almaas, Vibeke Marie Dejgaard, Lars A Saberniak, Jørg Leren, Ida S Berge, Knut Erik Haugaa, Kristina H Edvardsen, Thor |
author_sort | Haland, Trine F |
collection | PubMed |
description | OBJECTIVE: We explored cardiac volumes and the effects on systolic function in hypertrophic cardiomyopathy (HCM) patients with left ventricular hypertrophy (HCM LVH+) and genotype-positive patients without left ventricular hypertrophy (HCM LVH−). METHODS: We included 180 HCM LVH+, 100 HCM LVH− patients and 80 healthy individuals. End-Diastolic Volume Index (EDVI), End-Systolic Volume Index (ESVI) and ejection fraction (EF) were assessed by echocardiography. Left ventricular (LV) global longitudinal strain (GLS) was measured by speckle tracking echocardiography. RESULTS: EDVI and ESVI were significantly smaller in HCM LVH+ compared with HCM LVH− patients (41±14 mL/m(2) vs 49±13 mL/m(2) and 16±7 mL/m(2) vs 19±6 mL/m(2), respectively, both p<0.001) and in healthy individuals (41±14 mL/m(2) vs 57±14 mL/m(2) and 16±7 mL/m(2) vs 23±9 mL/m(2), respectively, both p<0.001). HCM LVH− patients had significantly lower EDVI and ESVI compared with healthy individuals (49±13 mL/m(2) vs 57±14 mL/m(2) and 19±6 mL/m(2) vs 23±9 mL/m(2), both p<0.001). EF was similar (61%±7% vs 60%±8% vs 61%±6%, p=0.43) in the HCM LVH+, HCM LVH– and healthy individuals, despite significantly worse GLS in the HCM LVH+ (−16.4%±3.7% vs −21.3%±2.4% vs −22.3%±3.7%, p<0.001). GLS was worse in the HCM LVH− compared with healthy individuals in pairwise comparison (p=0.001). Decrease in ESVI was closely related to EF in HCM LVH+ and HCM LVH− (R=0.45, p<0.001 and R=0.43, p<0.001) as expected, but there was no relationship with GLS (R=0.02, p=0.77 and R=0.11, p=0.31). Increased maximal wall thickness (MWT) correlated significantly with worse GLS (R=0.58, p<0.001), but not with EF (R=0.018, p=0.30) in the HCM LVH+ patients. CONCLUSION: HCM LVH+ had smaller cardiac volumes that could explain the preserved EF, despite worse GLS that was closely related to MWT. HCM LVH− had reduced cardiac volumes and subtle changes in GLS compared with healthy individuals, indicating a continuum of both volumetric and systolic changes present before increased MWT. |
format | Online Article Text |
id | pubmed-5471858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Open Heart |
record_format | MEDLINE/PubMed |
spelling | pubmed-54718582017-07-03 The systolic paradox in hypertrophic cardiomyopathy Haland, Trine F Hasselberg, Nina E Almaas, Vibeke Marie Dejgaard, Lars A Saberniak, Jørg Leren, Ida S Berge, Knut Erik Haugaa, Kristina H Edvardsen, Thor Open Heart Heart and Cardiomyopathies OBJECTIVE: We explored cardiac volumes and the effects on systolic function in hypertrophic cardiomyopathy (HCM) patients with left ventricular hypertrophy (HCM LVH+) and genotype-positive patients without left ventricular hypertrophy (HCM LVH−). METHODS: We included 180 HCM LVH+, 100 HCM LVH− patients and 80 healthy individuals. End-Diastolic Volume Index (EDVI), End-Systolic Volume Index (ESVI) and ejection fraction (EF) were assessed by echocardiography. Left ventricular (LV) global longitudinal strain (GLS) was measured by speckle tracking echocardiography. RESULTS: EDVI and ESVI were significantly smaller in HCM LVH+ compared with HCM LVH− patients (41±14 mL/m(2) vs 49±13 mL/m(2) and 16±7 mL/m(2) vs 19±6 mL/m(2), respectively, both p<0.001) and in healthy individuals (41±14 mL/m(2) vs 57±14 mL/m(2) and 16±7 mL/m(2) vs 23±9 mL/m(2), respectively, both p<0.001). HCM LVH− patients had significantly lower EDVI and ESVI compared with healthy individuals (49±13 mL/m(2) vs 57±14 mL/m(2) and 19±6 mL/m(2) vs 23±9 mL/m(2), both p<0.001). EF was similar (61%±7% vs 60%±8% vs 61%±6%, p=0.43) in the HCM LVH+, HCM LVH– and healthy individuals, despite significantly worse GLS in the HCM LVH+ (−16.4%±3.7% vs −21.3%±2.4% vs −22.3%±3.7%, p<0.001). GLS was worse in the HCM LVH− compared with healthy individuals in pairwise comparison (p=0.001). Decrease in ESVI was closely related to EF in HCM LVH+ and HCM LVH− (R=0.45, p<0.001 and R=0.43, p<0.001) as expected, but there was no relationship with GLS (R=0.02, p=0.77 and R=0.11, p=0.31). Increased maximal wall thickness (MWT) correlated significantly with worse GLS (R=0.58, p<0.001), but not with EF (R=0.018, p=0.30) in the HCM LVH+ patients. CONCLUSION: HCM LVH+ had smaller cardiac volumes that could explain the preserved EF, despite worse GLS that was closely related to MWT. HCM LVH− had reduced cardiac volumes and subtle changes in GLS compared with healthy individuals, indicating a continuum of both volumetric and systolic changes present before increased MWT. Open Heart 2017-05-16 /pmc/articles/PMC5471858/ /pubmed/28674623 http://dx.doi.org/10.1136/openhrt-2016-000571 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Heart and Cardiomyopathies Haland, Trine F Hasselberg, Nina E Almaas, Vibeke Marie Dejgaard, Lars A Saberniak, Jørg Leren, Ida S Berge, Knut Erik Haugaa, Kristina H Edvardsen, Thor The systolic paradox in hypertrophic cardiomyopathy |
title | The systolic paradox in hypertrophic cardiomyopathy |
title_full | The systolic paradox in hypertrophic cardiomyopathy |
title_fullStr | The systolic paradox in hypertrophic cardiomyopathy |
title_full_unstemmed | The systolic paradox in hypertrophic cardiomyopathy |
title_short | The systolic paradox in hypertrophic cardiomyopathy |
title_sort | systolic paradox in hypertrophic cardiomyopathy |
topic | Heart and Cardiomyopathies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471858/ https://www.ncbi.nlm.nih.gov/pubmed/28674623 http://dx.doi.org/10.1136/openhrt-2016-000571 |
work_keys_str_mv | AT halandtrinef thesystolicparadoxinhypertrophiccardiomyopathy AT hasselbergninae thesystolicparadoxinhypertrophiccardiomyopathy AT almaasvibekemarie thesystolicparadoxinhypertrophiccardiomyopathy AT dejgaardlarsa thesystolicparadoxinhypertrophiccardiomyopathy AT saberniakjørg thesystolicparadoxinhypertrophiccardiomyopathy AT lerenidas thesystolicparadoxinhypertrophiccardiomyopathy AT bergeknuterik thesystolicparadoxinhypertrophiccardiomyopathy AT haugaakristinah thesystolicparadoxinhypertrophiccardiomyopathy AT edvardsenthor thesystolicparadoxinhypertrophiccardiomyopathy AT halandtrinef systolicparadoxinhypertrophiccardiomyopathy AT hasselbergninae systolicparadoxinhypertrophiccardiomyopathy AT almaasvibekemarie systolicparadoxinhypertrophiccardiomyopathy AT dejgaardlarsa systolicparadoxinhypertrophiccardiomyopathy AT saberniakjørg systolicparadoxinhypertrophiccardiomyopathy AT lerenidas systolicparadoxinhypertrophiccardiomyopathy AT bergeknuterik systolicparadoxinhypertrophiccardiomyopathy AT haugaakristinah systolicparadoxinhypertrophiccardiomyopathy AT edvardsenthor systolicparadoxinhypertrophiccardiomyopathy |